STOCK TITAN

Citius Pharmaceuticals (CTXR) Stock News, May-Sep 2023

CTXR NASDAQ

Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.66%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.20%
Tags
-
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.22%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags

FAQ

What is the current stock price of Citius Pharmaceuticals (CTXR)?

Citius Pharmaceuticals (CTXR) last closed at $0.5107.

What is the market cap of Citius Pharmaceuticals (CTXR)?

The market cap of Citius Pharmaceuticals (CTXR) is approximately $14.0M.